Chongqing University Cancer Hospital
Chongqing, China
NCT Number: NCT06550739
Background: Hepatocellular carcinoma (HCC) is a significant health problem in China, with high incidence and mortality rates. This study aimed to identify the prognostic factors of elderly HCC patients in southwest China and construct a new prognostic model for predicting overall survival (OS).
Methods: This retrospective cohort study collected clinical data from 958 patients with liver cancer on January 1, 2019, and December 12, 2020. The Cox regression model was used to test the significance of all available variables as prognostic factors of OS. Independent prognostic factors were identified based on multivariable analysis to model nomograms. The concordance index (C-index), the area under the receiver operating characteristic (AUC), the Time-dependent C-index, the Time-dependent AUC, the calibration curve, and decision curve analysis (DCA) were measured to assess the model performance of the nomogram.
Conclusions: The comprehensive risk prediction model for OS in HCC patients developed through this retrospective cohort study offers a promising avenue for improving clinical outcomes and patient care.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Chongqing, China
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Randomly divide the data into a training set and a validation set in a 7:3 ratio
Time frame: April 31, 2024
Patient survival or death
Haike Lei
Other
Development and Validation of a New Prognostic System for Patients With Hepatocellular Carcinoma: A Cohort Study in China
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04892810
Adenocarcinoma, Carcinoma
Grenoble, France
View Trial DetailsNCT04930315
Adenocarcinoma, Carcinoma
Hangzhou, Zhejiang, China
View Trial DetailsNCT05128032
Adenocarcinoma, Carcinoma
Boston, Massachusetts, United States
View Trial DetailsNCT04374877
Adenocarcinoma, Advanced Solid Tumor
Duarte, California, United States
View Trial Details